Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT

Jayne, David; Walsh, Michael; Merkel, Peter A; Peh, Chen Au; Szpirt, Wladimir; Puéchal, Xavier; Fujimoto, Shouichi; Hawley, Carmel; Khalidi, Nader; Jones, Rachel; Flossmann, Oliver; Wald, Ron; Girard, Louis; Levin, Adeera; Gregorini, Gina; Harper, Lorraine; Clark, William; Pagnoux, Christian; Specks, Ulrich; Smyth, Lucy; Ito-Ihara, Toshiko; de Zoysa, Janak; Brezina, Biljana; Mazzetti, Andrea; McAlear, Carol A; Reidlinger, Donna; Mehta, Samir; Ives, Natalie; Brettell, Elizabeth A; Jarrett, Hugh; Wheatley, Keith; Broadhurst, Elizabeth; Casian, Alina; Pusey, Charles D

doi:10.3310/pnxb5040

All Outputs (4)

Efficacy and safety of eculizumab in children with Shiga-toxin-producing Escherichia coli haemolytic uraemic syndrome: the ECUSTEC RCT (2024)
Journal Article
Ives, N., Woolley, R., Saleem, M. A., Moakes, C. A., Waters, A., Gilbert, R. D., Jarrett, H., Brettell, E., Nash, S., Farmer, L. K., Ourradi, K., & Johnson, S. A. (2024). Efficacy and safety of eculizumab in children with Shiga-toxin-producing Escherichia coli haemolytic uraemic syndrome: the ECUSTEC RCT. Health Technology Assessment, 11(11), 1-78. https://doi.org/10.3310/rfty4766

Background

Shiga-toxin-producing Escherichia coli haemolytic uraemic syndrome affects ~100 United Kingdom children each year. Around half need dialysis, a quarter develop serious complications with long-term consequences and ~3% die. No effective... Read More about Efficacy and safety of eculizumab in children with Shiga-toxin-producing Escherichia coli haemolytic uraemic syndrome: the ECUSTEC RCT.

Needle fasciotomy versus limited fasciectomy for the treatment of Dupuytren’s contractures of the fingers (Hand-2): study protocol for a randomised controlled trial (2024)
Journal Article
Harrison, S., Ogollah, R., Hollingworth, W., Mills, N., Karantana, A., Blazeby, J., Montgomery, A., Shafayat, A., Jarrett, H., & Davis, T. (2024). Needle fasciotomy versus limited fasciectomy for the treatment of Dupuytren’s contractures of the fingers (Hand-2): study protocol for a randomised controlled trial. Trials, 25(1), Article 398. https://doi.org/10.1186/s13063-024-08003-1

Background: Dupuytren’s contractures (DC) are fibrous cords under the skin of the hand that cause one or more fingers to curl gradually and irreversibly towards the palm. These contractures are usually painless but can cause a loss of hand function.... Read More about Needle fasciotomy versus limited fasciectomy for the treatment of Dupuytren’s contractures of the fingers (Hand-2): study protocol for a randomised controlled trial.

A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial (2023)
Journal Article
Bradbury, A. W., Moakes, C. A., Popplewell, M., Meecham, L., Bate, G. R., Kelly, L., Chetter, I., Diamantopoulos, A., Ganeshan, A., Hall, J., Hobbs, S., Houlind, K., Jarrett, H., Lockyer, S., Malmstedt, J., Patel, J. V., Patel, S., Rashid, S. T., Saratzis, A., Slinn, G., …Deeks, J. J. (2023). A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial. Lancet, 401(10390), 1798-1809. https://doi.org/10.1016/s0140-6736%2823%2900462-2

Background
Chronic limb-threatening ischaemia is the severest manifestation of peripheral arterial disease and presents with ischaemic pain at rest or tissue loss (ulceration, gangrene, or both), or both. We compared the effectiveness of a vein bypa... Read More about A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial.

Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT (2022)
Journal Article
Jayne, D., Walsh, M., Merkel, P. A., Peh, C. A., Szpirt, W., Puéchal, X., Fujimoto, S., Hawley, C., Khalidi, N., Jones, R., Flossmann, O., Wald, R., Girard, L., Levin, A., Gregorini, G., Harper, L., Clark, W., Pagnoux, C., Specks, U., Smyth, L., …Pusey, C. D. (in press). Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT. Health Technology Assessment, 26(38), https://doi.org/10.3310/pnxb5040

Background
Anti-neutrophil cytoplasm antibody-associated vasculitis (AAV) is an inflammatory multisystem autoimmune disease that frequently involves the lungs and kidneys, resulting in end-stage renal disease and premature death. Treatment with high... Read More about Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT.